ABL001 is named as an intervention in 5 current clinical trials in our USA, China, Germany, France, Italy, Japan, South Korea, Taiwan, Israel, UK, Spain, Netherlands, Denmark, Austria, Czechia, Portugal, Canada, Singapore, Australia, Poland, Turkey, India, Belgium, Sweden, Switzerland, Norway, Brazil and Mexico registers. 4 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Novartis Pharmaceuticals (4). The most-studied condition is Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Marlise Luskin, MD | 1 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our USA, China, Germany, France, Italy, Japan, South Korea, Taiwan, Israel, UK, Spain, Netherlands, Denmark, Austria, Czechia, Portugal, Canada, Singapore, Australia, Poland, Turkey, India, Belgium, Sweden, Switzerland, Norway, Brazil and Mexico registers name ABL001 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 5 trials are recruiting: 2 with sites in USA, 2 with sites in China, 2 with sites in Germany, 2 with sites in France, 2 with sites in Italy, 2 with sites in Japan, 2 with sites in South Korea, 2 with sites in Taiwan, 2 with sites in Israel, 1 with sites in UK, 1 with sites in Spain, 1 with sites in Netherlands, 1 with sites in Denmark, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Portugal, 1 with sites in Canada, 1 with sites in Singapore, 1 with sites in Australia, 2 with sites in Poland, 2 with sites in Turkey, 1 with sites in Brazil and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Novartis Pharmaceuticals (4) and Marlise Luskin, MD (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ABL001 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ABL001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ABL001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.